Federal Register #2026-14346

NCI Seeks Licensees for Advanced Adoptive Cell Therapy Technologies

The National Cancer Institute (NCI), part of the National Institutes of Health, is seeking licensees and research partners to commercialize and co-develop advanced adoptive cell therapies for cancer and chronic viral infections. - Government Buyer: - National Institutes of Health (NIH) - National Cancer Institute (NCI) - OEMs and Vendors: - No specific OEMs or commercial vendors are named; the opportunity is for licensing government-owned inventions and methods developed by NCI. - Products/Services Requested: - Licensing and commercialization of T cell receptor (TCR)-engineered T cells expressing murine/human hybrid receptors - Method enables GMP production of personalized T cell therapy products targeting tumor-specific mutations - Enhances persistence and performance of T cells after adoptive transfer - Licensing and commercialization of Papilloma Infiltrating Lymphocyte (PIL) cell therapy products - Manufacturing method for PIL cell therapy to treat chronic HPV 6 or 11 infections (e.g., recurrent respiratory papillomatosis, anogenital condyloma) - Unique or Notable Requirements: - Licensees must be capable of manufacturing and commercializing advanced cell therapy products using NCI's proprietary methods - Technologies are intended for personalized oncology and chronic viral infection applications - No specific product quantities or part numbers are provided, as this is a technology licensing and co-development opportunity - Technologies are in advanced clinical development and have international patent protection

Description

The National Cancer Institute (NCI) seeks capable licensees interested in commercializing T cell receptor (TCR)-engineered T cells expressing murine/human hybrid receptors. This technology enables the selective expansion of engineered T lymphocytes under GMP conditions, improving the production of personalized T cell therapy products. The method enhances therapeutic benefits by increasing the frequency and performance of tumor-specific T cells and reducing risks associated with mis-pairing of TCR chains. NCI aims to license this method to facilitate adoptive cell therapy processes.

View original listing